A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC.

被引：0
|
作者：
Ricciuti, Biagio [1 ]
Arbour, Kathryn C. [2 ]
Mahadevan, Navin R. [3 ]
Alessi, Joao V. [1 ]
Lindsay, James [1 ]
Umeton, Renato [1 ]
Sinha, Rileen [1 ]
Hoojghan, Amir [1 ]
Vokes, Natalie [1 ]
Recondo, Gonzalo [1 ]
Lamberti, Giuseppe [1 ]
Polio, Andrew [1 ]
Rizvi, Hira [2 ]
Leonardi, Giulia [1 ]
Plodkowski, Andrew J. [2 ]
Felt, Kristen [1 ]
Sharma, Bijaya [1 ]
Tolstorukov, Michael Y. [1 ]
Janne, Pasi A. [1 ]
Van Allen, Eliezer M. [1 ]
Sholl, Lynette M. [3 ]
Rodig, Scott J. [3 ]
Hellmann, Matthew D. [2 ]
Awad, Mark M. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
490
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Predictive factors of response to PD-(L)1 inhibitors in patients with advanced non-small cell lung (NSCLC) and high PD-L1 expression
    Barba Joaquin, A.
    Piedra, A.
    Mosquera, J.
    Riudavets, M.
    Gomez-Randulfe, M. I.
    Garcia Campelo, M. R.
    Sullivan, I. G.
    Serra, J.
    Aguado, M.
    Majem Tarruella, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S768 - S769
  • [42] The decrease of TMB, TNB and HLA expression are the mechanism of drug resistance of NSCLC to immunosuppressive PD-1/PD-L1
    Yu, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 508 - 508
  • [43] Prevalence of PD-L1 Expression Rates in Different NSCLC Specimens
    Holmes, M.
    Mahar, A.
    Lum, T.
    Boyer, M.
    Kao, S.
    Cooper, W.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S506 - S506
  • [44] The association between BIM deletion polymorphism and treatment efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC.
    Zhang, Dai
    Li, Xuanzong
    Huang, Caimei
    Fan, Xinyu
    Qin, Wenru
    Yang, Linlin
    Wang, Linlin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression
    Kunimasa, Kei
    Nakamura, Harumi
    Nishino, Kazumi
    Nakatsuka, Shin-ichi
    Kumagai, Toru
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E231 - E233
  • [46] Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+NSCLC patients
    Griesinger, F.
    Kowanetz, M.
    Zou, W.
    Shames, D. S.
    Cummings, C. A.
    Rizvi, N. A.
    Spira, A.
    Frampton, G.
    Leveque, V.
    Flynn, S.
    Mocci, S.
    Shankar, G.
    Funke, R.
    Ballinger, M.
    Waterkamp, D.
    Chen, D. S.
    Sandler, A.
    Hampton, G.
    Amler, L. C.
    Hedge, P.
    Hellmann, M. D.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 220 - +
  • [47] Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies
    Jeong, Ah-Reum
    Trando, Aaron H.
    Thomas, Sean D.
    Riviere, Paul
    Sakowski, Patrick J.
    Sokol, Ethan S.
    Goodman, Aaron M.
    Kurzrock, Razelle
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [48] Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+NSCLC Patients
    Kowanetz, Marcin
    Zou, Wei
    Shames, David
    Cummings, Craig
    Rizvi, Naiyer
    Spira, Alexander
    Frampton, Garrett
    Leveque, Vincent
    Flynn, Susan
    Mocci, Simonetta
    Shankar, Geetha
    Funke, Roel
    Ballinger, Marcus
    Waterkamp, Daniel
    Chen, Daniel
    Sandler, Alan
    Hampton, Garret
    Amler, Lukas
    Hegde, Priti
    Hellmann, Matthew
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S321 - S322
  • [49] Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.
    George, Thomas J.
    Frampton, Garrett Michael
    Sun, James
    Gowen, Kyle
    Kennedy, Mark
    Greenbowe, Joel R.
    Schrock, Alexa Betzig
    Ali, Siraj Mahamed
    Klempner, Samuel Jacob
    Flezel, Aram F.
    Ross, Jeffrey S.
    Stephens, Phil
    Miller, Vincent A.
    Fabrizio, David
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Clinical significance of inter-assay discrepancy in PD-L1 expression evaluation for the efficacy of pembrolizumab in advanced NSCLC patients with high PD-L1 expression
    Miyakoshi, Jun
    Kashima, Jumpei
    Shirasawa, Masayuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Horinouchi, Hidehito
    Shiraishi, Kouya
    Kohno, Takashi
    Yamamoto, Noboru
    Yatabe, Yasushi
    Ohe, Yuichiro
    CANCER RESEARCH, 2024, 84 (06)
12345